CORPORATE PRESENTATION

June 2017

1

DisclaimerCautionary StatementsThis presentation contains “forward-looking statements” within the meaning of the federal securities laws. Except for historical information contained herein, the statements in this presentation are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements made herein relate to, among other things, future sales, earnings, return on equity, cost savings, process improvements, free cash flow, share repurchases, capital expenditures, acquisitions, benefits of investments and partnerships, business strategies and other matters. Such statements can be identified by words such as: “expected,” “expects,” “expect,” “forecast,” “would,” “estimate,” “will,” or similar references to future periods.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results could differ materially from those stated or implied in the forward-looking statements. For a list of factors, risks and uncertainties which could make our actual results differ from expected results, please see our latest Annual Report on Form 10-K. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, as a result of new information, future developments or otherwise.

This presentation also contains non-GAAP financial information. Management uses this information in its internal analysis of results and believes this information may be informative to investors in gauging the quality of our financial performance, identifying trends in our results and providing meaningful period-to-period comparisons. For definitions of applicable non-GAAP financial measures and reconciliations of non-GAAP financial information to GAAP financial information, see the Reconciliations of GAAP to Non-GAAP Financial Measures included in the Company’s financial reports on Forms 10-Q and 10-K and related press releases.

2

Bio-Techne Business OverviewAt a Glance:President and CEO: Chuck KummethHeadquarters: Minneapolis, MNNumber of Employees: 1,700FY2016 Revenues: $499 millionNASDAQ: TECHMarket Cap: $4.2B

Market Profile:Leader in:- Life Science Consumables Market- Automated Protein Analysis Solutions- Controls & Calibrators for IVD Assays- Molecular Anatomic PathologyAddressable Market Size: ~$5-10 billion

Key Product Lines and Workstreams:Biological ContentAutomated Western BlotSingle and Multiplex ImmunoAssaysRNA-ISH Molecular Diagnostics

36%

23%

25%

17%

Revenue by Customer Segmentation

Pharma/Biotech

Academia

OEM

Distributors

59%27%

14%

Revenue by Geography

Americas EMEA APAC

3

Our Vision

• Expanding our product portfolio with New & Innovative research tools

• Delivering more complete solutions for our customers through a greater diversity of technologies

• Geographic expansion with continued focus on China

• Focusing on products that bring us closer to the “clinic” by focusing on diagnostic and bioprocess applications

• Extracting maximal value from the “treasure trove” of reagents developed over the 40 years we have been in business via collaborations and licensing opportunities

4

Our Mission

80%

12%

8%

Headcount by Geography

North America

EMEA

APAC

1,700Employees

5

In excess of 200 employees hold PhD degree

A Great Big Welcome and Hello

North America

Minneapolis

San Marcos

Devens

Cambridge

San Jose

Newark

Emeryville

Littleton

Oakville

Toronto

Ottawa

Wallingford

Europe

Abingdon

Langley

Bristol

Wiesbaden

Lille

Milan

Zug

Asia

Shanghai

Beijing

Hong Kong

Singapore

Tokyo

Total Geographic Sites – 24Total WW Employees - 1700

Global Locations

6

Subsidiary Model

Divisions (Own Strategy)

BioTechnology

Diagnostics

Protein Platforms

Regions (Own Execution)

Americas

EMEA

APAC

Collaboration Structure

- Commercial teams collaborations

- Global prioritization

- Global capital planning

- M&A

7

Current Reportable Segments & Brands

~64% of Sales~80% Gross Margin

Low 50s Op. Margin%

~15% of SalesHigh 60s GM%

High single-digit OM%

~21% of SalesMid 40s Gross Margin%

~ 30% Op. Margin

Note: All margin percentages have been adjusted to exclude impact of acquisition costs

Biotechnology

Diagnostics

Protein Platforms

8

Large Addressable Markets

Customers Served

o Pharma

o Biotech

o Academia

o CROs

o Hospitals

o Foundations

o Government

$5B-$10B Addressable

Market

4-10% CAGR

Life Science Research Reagents

$1.8B Tumor Biology $0.8B

Stem Cells

$0.9B

Research Immunoassay

$0.7B

Diagnostics $4.2B

Clinical

Controls

$0.4B

BioProcess

Media

$1.6B

Single Cell Biology

$0.9B

Western Blot

$0.5B

Biologics Manufacturing

$0.6B

9

Minneapolis Headquarters Offices and Labs

10

Space: 950,000 ft2

Global Bio-Techne Locations

Abingdon, UK Office

Langley, UKWarehouse

Newark, CA ACD Office Devens, MA, Offices

Bristol, UK Offices

Shanghai PG labs

Milan, Italy Office

11

ProteinSimpleJapan Office

Pl

Collaboration Programs• Active collaboration with over 50 Key Opinion Leaders to better identify product needs

(Univ. of Minnesota, Mayo Clinic, Univ. of Pennsylvania, Stanford, etc.)

• Committed to educating life science researchers on BioTechne’s products and their role in enabling life science research activities

12

Pl

Our Business Today

Develop and manufactures biological reagents used in all aspects of life science research (Research Tools such as: proteins, antibodies, & immunoassays) and molecular probes for the Molecular Pathology market

Automated solutions that improve the efficiency of process work streams, such as: automated western blot instruments, bioprocess purity analyzers, microfluidic imaging instruments, multiplex-ELISA instruments, etc.

Provide controls, calibrators and diagnostic assays for the regulated diagnostic market, such as: hematology controls, blood gas and chemistry controls, diagnostic assays reagents

13

Bio

tech

no

logy

Div

isio

n

Dia

gno

stic

sD

ivis

ion

Pro

tein

Pla

tfo

rms

Div

isio

n

Proteins

Small MoleculesStem Cell

Products

StemXVivo®

ELISAs AntibodiesProteome

Profiler Arrays

LuminexRNA-ISH

Biotechnology Division

14

Separation

Imaging

Analysis

Microfluidics

Immunoassay

Measurement

Proteins are complex!

Protein Platforms Division

15

Diagnostics Division

16

17

Key Technologies with Diagnostic Applicability

•ACD’s RNAscope (RNA in-situHybridization)

•PPD’s Ella Multiplex Instrument

Ella

Acquired in August 2016

Newark, CA based company with ~150 employees

Developed technology to improve detection of genes and gene transcripts using probes (in-situ hybridization) with initial focus on RNA transcript detection (RNAScope)

Key technology improvements: Binding specificity to target RNA Better signal amplification (b-DNA) Retention of morphological context

Could be an aid to pathology practices where IHC reagents are deficient or lacking

13,000 current products, first commercialized in 2011, sold to both research and clinical customers

Advanced Cell Diagnostics

18RNAscope VENTANA LEICA

Probe: a synthetic short nucleic acid sequence complementary to the gene sequence of interest

Comparison of RNAscope® to other Dx Platforms for HPV Testing

RNAscope IHC DNA ISH

PCR

(Roche

Cobas)

Hybrid

Capture

(Qiagen HC2)

RT PCR

(Hologic

Aptima)

TargetHPV E6/E7

mRNAP16 HPV DNA HPV DNA HPV DNA

HPV E6/E7

mRNA

Evidence

of Viral

Activity

√ - - - - √

Morphologic

Context+++ +++ +++ - - -

Sensitivity +++ +++ + +++ ++ ++

Specificity +++ + +++ +++ +++ +++19

Fullfillment of an Unmet Need – In Situ RNA Analysis

• IHC and FISH are the leading tools for research & tissue diagnostics

• No sensitive and robust technology for in situ RNA detection prior to RNAscope

• RNAscope provides complementary information to FISH and IHC

DNA RNA Protein

FISH

1990s

IHC

1970s

RNAscope®

2012

20

Ella Features Suitable for Diagnostic Applications

Ella

• Addresses low-plex multi analyte immunoassay analysis: (16 samples/4 analytes)

• Parallel immunoassay operation, thus avoiding “cross-talk” between assays

• Hands off operation (removes operator bias)

• Quick turn around time (1 hr to results)

• Excellent performance (precision and dynamic range-4 log S/N)

• Embedded standard curve (removes need to run standard curve)

• Closed platform: (controls performance and biological sample handling)

• Small sample volume requirements (~25 mL)

• Small Footprint (WxDxH=37x54x26 cm)21

Targets with

ROIC > WACC

Targets that fill perceived gaps

Sound prioritization strategy

Healthy hopper of targets

Disciplined M&A and Investment Strategy

22

Bio-Techne Summary

23